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Neutralizing antibodyThe external domains of the HIV-1 envelope glycoprotein (gp120 and the gp41 ectodomain, collectively
known as gp140) contain all known viral neutralization epitopes. Various strategies have been used to create
soluble trimers of the envelope to mimic the structure of the native viral protein, including mutation of the
gp120–gp41 cleavage site, introduction of disulﬁde bonds, and fusion to heterologous trimerization motifs.
We compared the effects on quaternary structure, antigenicity, and immunogenicity of three such motifs: T4
ﬁbritin, a GCN4 variant, and the Escherichia coli aspartate transcarbamoylase catalytic subunit. Fusion of each
motif to the C-terminus of a noncleavable JRCSF gp140(-) envelope protein led to enhanced trimerization but
had limited effects on the antigenic proﬁle and CD4-binding ability of the trimers. Immunization of rabbits
provided no evidence that the trimerized gp140(-) constructs induced signiﬁcantly improved neutralizing
antibodies to several HIV-1 pseudoviruses, compared to gp140 lacking a trimerization motif. However,
modest differences in both binding speciﬁcity and neutralizing antibody responses were observed among the
various immunogens.
© 2009 Elsevier Inc. All rights reserved.Introduction
The ongoing HIV-1 epidemic has resulted in 2.7 million new
infections and 2.1 million AIDS deaths in 2007, for a total of 33 million
people living with HIV/AIDS (UNAIDS, 2008). Prophylactic measures
against HIV-1 are clearly required, and the discovery of vaccine
candidates that elicit broadly neutralizing antibody responses against
HIV-1 is an important goal (Karlsson Hedestam et al., 2008;a virus; ATC, E. coli aspartate
artate transcarbamoylase; BN-
LISA, enzyme-linked immuno-
variant form of GCN4 trimeric
ich the cleavage site between
TC, ATC with an N-terminal
tibody; T4F, the trimerization
Whalen).
55 Adams Drive, Menlo Park,
ll rights reserved.Monteﬁori et al., 2007; Walker and Burton, 2008). Some insights for
vaccine research can be gained from a better understanding of the
antibody response to HIV-1 during natural infection. Most HIV-
infected individuals develop neutralizing antibodies with limited
cross-reactivity (Hu and Stamatatos, 2007; Karlsson Hedestam et al.,
2008; Richman et al., 2003), a result that is likely due to the
predominance of autologous neutralization determinants in envelope
(Env) glycoproteins. However, the existence of some patients who go
on to develop broadly neutralizing immune sera suggests that such
antibodies can be elicited under certain conditions (Binley et al., 2008;
Carotenuto et al., 1998; Li et al., 2007; Pilgrim et al., 1997; Sather et al.,
2009). Several monoclonal antibodies (mAbs) capable of neutralizing
a broad range of primary isolates from various subtypes have been
isolated from HIV-1-infected individuals. These demonstrate that
conserved neutralization epitopes are present in Env (Binley et al.,
2004; Calarese et al., 2003; Saphire et al., 2001; Sharon et al., 2003;
Zwick et al., 2001). Studies with nonhuman primates have further
demonstrated that broadly neutralizing antibodies can protect from
infection (Baba et al., 2000; Hessell et al., 2009; Hofmann-Lehmann et
al., 2001; Mascola, 2003; Nishimura et al., 2002; Shibata et al., 1999).
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zation will confer somemeasure of protection against HIV-1 infection,
it is clear that current Env immunogens elicit antibodies that
neutralize only a small fraction of circulating isolates (Monteﬁori et
al., 2007).
The HIV-1 Env complex on the surface of infectious viral particles
is the target of neutralizing antibodies. This complex is formed by a
trimer of heterodimers of the gp120 and gp41 subunits of the Env
transmembrane protein (Dey et al., 2008; Hu and Stamatatos, 2007;
Karlsson Hedestam et al., 2008; Poignard et al., 2003, 2001). The Env
structures on the viral membrane are apparently heterogeneous (Dey
et al., 2008; Moore et al., 2006; Poignard et al., 2003; Sougrat et al.,
2007). Only complexes formed by intact gp120–gp41 trimers are
thought to be functional and capable of mediating HIV-1 entry into
target cells (Moore et al., 2006; Poignard et al., 2003, 2001).
Nonfunctional forms of Env could serve as decoys to prevent the
host immune system from recognizing conserved neutralization
epitopes (Dey et al., 2008; Moore et al., 2006; Poignard et al., 2003).
Recent cryoelectron tomographic studies on SIV and HIV-1 particles
have provided further evidence that the viral Env forms three-lobed
trimeric structures containing the membrane-distal gp120, with
considerable heterogeneity (Liu et al., 2008; Sougrat et al., 2007;
Zanetti et al., 2006; Zhu et al., 2006).
Clinical testing of several vaccines based on gp120 has shown a lack
of protective efﬁcacy (Pitisuttithum et al., 2006). Some investigators
have proposed that soluble trimers of the gp120–gp41 Env ectodomain
(i.e., lacking the transmembraneand cytoplasmicdomains)mightbetter
preserve or mimic the structure of functional Env complexes (Burton et
al., 2004; Schulke et al., 2002; Srivastava et al., 2003b; Yang et al., 2002;
Zhang et al., 2007). The inclusion of the gp41 ectodomain sequences is
also likely to be a positive factor in immunogenicity (Grundner et al.,
2004) since gp41 contains helical regions that often harbor T-helper
epitopes,. The Env ectodomain contains all of the known neutralization
epitopes. This gp140polypeptide, if cleaved at thegp120–gp41 junction,
will typically result in free gp120 subunits along with a thermodynam-
ically favored 6-helix bundle formed by the gp41 moiety. Mutating the
furin cleavage site to inhibit processing of gp140 creates a polypeptide
[referred to as gp140(-)] that has a tendency to form a range of
heterogeneous oligomers (Earl et al., 1994; Yang et al., 2000a, 2000b,
2002), although some modiﬁcations can stabilize oligomerization
(Srivastava et al., 2003a). These modiﬁed gp140 immunogens induce
high avidity antibodies in rabbits that are less focused on linear V3
epitopes, suggesting a possible beneﬁt to using noncleavable gp140
(Sharma et al., 2006). Another modiﬁed form of gp140, called
gp140ΔCFI, lacks the gp120–gp41 cleavage site, the fusion peptide,
and interhelical regions. This protein was shown to elicit an improved
antibody response compared to a series of other Env forms (Chakrabarti
et al., 2002). A recent study using Env immunogens from the HIV-1 R2
strain demonstrated that gp140(-) elicited broader and more potent
neutralization responses than did gp120 (Zhang et al., 2007).
Several studies have shown that cleavage-defective Env proteins
are antigenically different from processed Env (Binley et al., 2000;
Herrera et al., 2005; Moore et al., 2006; Pancera andWyatt, 2005). It is
therefore not clear to what extent the structure of gp140(-) resembles
native, fusion-competent Env complexes. To express processed and
stable trimers of gp140, Binley et al. introduced an intermolecular
disulﬁde bond between the gp120 and gp41 subunits to form a
complex called SOS gp140 (Binley et al., 2000). Although still
predominantly monomeric, SOS gp140 reacted more strongly with
the neutralizing b12mAb and less strongly with non-neutralizing
antibodies compared to a noncleavable gp140 that was composed of a
mixture of noncovalently associated and disulﬁde-linked dimers,
trimers, and tetramers (Schulke et al., 2002). Subsequently, an
isoleucine-to-proline substitution was introduced at position 559 in
the N-terminal heptad region of gp41 to increase the stability of SOS
gp140 (Sanders et al., 2002). This SOSIP gp140 variant is fully cleaved,has desirable antigenic properties, and is predominantly trimeric
(Sanders et al., 2002). Immunogenicity studies using rabbits showed
that SOSIP gp140 trimers elicited approximately threefold lower titers
of anti-gp120 antibodies than did monomeric gp120 with similar
neutralization proﬁles (Beddows et al., 2005). More recently, speciﬁc
amino acids in the N-terminus of the gp41 ectodomain have been
shown to further enhance the stability of SOSIP gp140 trimers (Dey et
al., 2007). These substitutions in the Env polypeptide reduced the
expression of nontrimeric envelope forms on pseudoviruses and were
associated with a decreased binding of non-neutralizing antibodies
(Dey et al., 2008).
Several small trimerization motifs have been fused to the C-
terminus of gp140(-) to stabilize the formation of Env trimers. Among
them are a 32-amino-acid form of the GCN4 transcription factor
(GCN), a 27-amino-acid trimerization domain from the C-terminus of
bacteriophage T4 ﬁbritin (T4F), and a soluble trimerization domain of
chicken cartilage matrix (CART) protein (Selvarajah et al., 2008; Yang
et al., 2000a, 2002). Fusion of these motifs promotes trimer formation
of gp140(-), which exhibits preferential binding to the neutralizing
mAbs b12 and 2G12 with reduced binding to non-neutralizing
antibodies (Selvarajah et al., 2008; Yang et al., 2000b, 2002).
Immunization of rabbits with the gp140(-)GCN fusion protein elicited
neutralizing antibodies of greater potency and breath than did either
gp120 or solid-phase proteoliposomes containing a cleavage-defec-
tive Env (Grundner et al., 2005). A separate immunization study using
mice showed that the gp140(-)T4F fusion was only marginally more
effective than gp120 at eliciting neutralizing antibodies (Bower et al.,
2006).
Another trimerization domain that has been fused to gp140 is the
catalytic chain of aspartate transcarbamoylase (ATCase). The ATCase
holoenzyme is composed of 12 polypeptide subunits with 6 catalytic
chains (34 kDa each) and 6 regulatory chains (17 kDa each). The
catalytic chains (ATC) are packed into 2 trimers and the catalytic
center is composed of residues from adjacent chains within a trimer
(Helmstaedt, Krappmann, and Braus, 2001). Consequently, ATCase
enzyme activity serves as a convenient way to detect trimerization of
an Env–ATC fusion protein. Chen et al. reported that fusion of ATC
signiﬁcantly stabilized SIVmac32H gp140(-) trimers and allowed the
puriﬁcation of a homogeneous fusion protein that retained ATCase
activity (Chen et al., 2004). In the present study, we show that the ATC
polypeptide has a similar stabilizing effect on an HIV-1 gp140
molecule. We then compare the quaternary structure, antigenicity,
and immunogenicity of gp140(-) fusion proteins created using the
ATC, T4F, and GCN trimerization motifs.
Results
Effect of trimerization motifs on expression of JRCSF gp140
We fused the coding sequences of the T4F and ATC trimerization
motifs to the 3′ end of a gene encoding gp140 from the JRCSF strain of
HIV-1 as described in Materials and Methods. The expression plasmid
constructs were transfected into COS-7 cells, along with plasmids
expressing JRCSF gp120 and gp140. Western blot analysis showed
that both fusion constructs produced roughly equal amounts of
intracellular and secreted protein, similar to that of unmodiﬁed gp140
(Fig. 1A). Cleavage of gp140 was incomplete in all three cases, and the
proportion of gp120 varied, ranging from 10% to 30% of the uncleaved
polypeptide (Fig. 1A, lanes 6–8).
We next compared the effect of the ATC, GCN and T4F trimeriza-
tion motifs on noncleavable JRCSF gp140(-). The mutations intro-
duced into the primary and secondary furin cleavage site of gp140(-)
were based on those reported previously in the design of uncleaved
SF162 gp140 (Srivastava et al., 2003a). Transient transfections were
performed using both COS-7 and HEK-293 cells. Western blot analysis
showed that the expression levels of gp140 and gp140(-) were similar
Fig. 1. Effect of trimerization motifs on JRCSF gp140 and gp140(-) expression.
Expression plasmids were transiently transfected into the indicated cells and incubated
for 3 days in serum-free medium. Envelope expression was analyzed by Western blot
using a mouse polyclonal anti-gp120 serum (Du et al., 2008). Equal volumes of puriﬁed
JRCSF gp120 at the indicated concentrations were analyzed as controls on the same gel.
Lane numbers are indicated at the bottom of each blot image. (A) Transient transfection
of plasmids encoding gp120 (Du et al., 2008), gp140, gp140ATC, and gp140T4F in COS-7
cells. Ten microliters of each supernatant and an equivalent amount of cellular extract
were loaded on SDS–PAGE. (B) Transient transfection of plasmids encoding gp140,
gp140(-), gp140(-)ATC, gp140(-)GCN, and gp140(-)T4F in COS-7 and HEK-293 cells.
Ten μl of each supernatant were loaded on SDS–PAGE. The concentrations of the
puriﬁed JRCSF gp120 controls for COS-7 and HEK-293 transfections are given above and
below the Western blot images, respectively.
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cleavage sites were sufﬁcient to prevent cleavage of gp140(-) in both
cell types (Fig. 1B). The presence of the T4F and GCN motifs did not
affect the expression level of gp140(-), while the ATC polypeptide
reduced expression by up to 50% (Fig. 1A, lane 7; Fig. 1B, lane 3).
Based on the above ﬁndings, we chose to study fusion proteins
based on gp140(-) to avoid potential complications arising from a
mixture of cleaved and uncleaved gp140 forms. Since the expression
of codon-optimized Env genes was ∼2-fold to 3-fold higher in HEK-
293 cells compared to COS-7 cells (Fig. 1B), we decided to use HEK-
293 cells for most of the experiments. However, COS-7 cells were used
to transiently express Env genes for partial puriﬁcation and blue
native PAGE (BN-PAGE) analysis since this cell line is easier to handle
than HEK-293 cells, particularly at large scale.
Trimerization motifs promote trimer formation of noncleavable JRCSF
gp140
The gp140 variants were transiently expressed in COS-7 cells (Fig.
1B), puriﬁed using Galanthus nivalis agglutinin–agarose columns, andseparated on BN-PAGE. Fig. 2A shows that both gp140 and gp140(-)
consist of a mixture of dimer, trimer, and higher oligomers, with
dimers being predominant. In contrast, gp140(-)T4F, gp140(-)GCN,
and gp140(-)ATC were all composed of a predominant trimer
population, demonstrating that addition of any of the three motifs
to the C-terminus of gp140(-) stabilizes trimers (Fig. 2A, compare
lanes 2, 4, and 5 to lanes 3 and 6).
Since ATC exhibits enzymatic activity only when the catalytic
subunits form a trimer (Chen et al., 2004; Helmstaedt et al., 2001), we
further investigated the efﬁciency of gp140(-)ATC trimer formation
using an ATCase enzyme assay. We transfected HEK-293 cells with a
plasmid encoding ATC fused to an N-terminal hexahistidine tag (H6.
ATC) and analyzed the supernatant on Western blot (Fig. 2B). We
found that a potential N-glycosylation site, predicted by the ATC
polypeptide sequence, was occupied in more than 50% of HEK-293-
expressed H6.ATC (Fig. 2B, compare lanes 1–4 with 5–6). When
compared to a recombinant H6.ATC expressed in and puriﬁed from
Escherichia coli, the HEK-293-expressed H6.ATC showed a ∼4-fold
reduction in its EC50 (Fig. 2C), possibly due to the steric effects of the
N-glycan on the active site. The gp140(-) and gp140(-)ATC constructs
were also expressed in HEK-293. Compared to the nonspeciﬁc
background given by gp140(-), the gp140(-)ATC protein exhibited
clearly detectable ATCase activity, although the EC50 value was 3.5-
fold lower than that of the H6.ATC expressed in HEK-293 cells. The
enzymatic activity of the gp140(-)ATC protein conﬁrms that trimers
are formed. Since our BN-PAGE results showed that the majority of
gp140(-) ATC is trimeric, the relatively low ATCase activity (Fig. 2C) is
likely due to the formation of a suboptimal active site.
Antigenicity and CD4-binding activities of various forms of JRCSF gp140
Antigenicity is one of the criteria used to judge to what extent a
soluble trimeric gp140 mimics the conformation of functional viral
Env complexes. It has been previously observed that functional
trimers preferentially bind to broadly neutralizing antibodies such as
2G12 and b12 relative to non-neutralizing antibodies such as b6
(Moore et al., 2006; Poignard et al., 2003; Yang et al., 2002). To
analyze the binding activities of the gp140(-) fusion proteins to
monoclonal antibodies and CD4–Ig, we transfected HEK-293 cells
with plasmids encoding JRCSF gp140, gp140(-), the three gp140(-)
trimeric motif constructs, and JRCSF gp120. The expression levels
were quantitated using Western blot, the concentrations of each
gp120 or gp140 polypeptide were normalized to 75 nM, and equal
volumes were used to coat 96-well plates for ELISA.
The coating efﬁciencies of these proteins were determined using a
polyclonal antiserum to gp120 called P31JR (Fig. 3). The amounts of
gp140, gp140(-), gp140(-)T4F, and gp140(-)GCN protein bound to
each well were very similar, whereas that of gp140(-)ATC was
somewhat less. The amounts of gp140 boundwere substantially lower
than that of gp120; binding signals with P31JR were half those of
gp120. The effect of non-Env proteins in the culture supernatants on
coating was evaluated by comparing a 75 nM sample of puriﬁed JRCSF
gp120 with the HEK-293 culture supernatant containing the same
concentration of gp120.We found that the P31JR-binding curves were
identical in two independent experiments (data not shown),
suggesting that extraneous proteins do not interfere with plate
coating in these experiments.
The supernatant-coated plates were probedwith serial dilutions of
2F5, 2G12, b6, b12, and CD4–Ig. As shown in Fig. 3, the ligand-binding
activities of gp140, gp140(-), and the three gp140(-) trimeric motif
fusions largely tracked their relative binding of P31JR, suggesting that
mutations in the furin cleavage site as well as trimerization did not
affect binding of the various monoclonal antibodies or CD4–Ig.
With the exception of gp140(-)ATC, all four gp140 variants bound
2G12 and b12 as well as or better than gp120, whereas they all bound
to b6 more weakly than gp120 (Fig. 3). Although gp140(-)ATC bound
Fig. 2. Effect of trimerization motifs on oligomerization of gp140(-). (A) BN-PAGE analysis of trimer formation. Env proteins from the COS-7 transfections shown in Fig. 1B were
puriﬁed by lectin afﬁnity resin and run on BN-PAGE gels. Puriﬁed JRFL gp120 (Schulke et al., 2002) was run in parallel as a control. The expected positions of monomers, dimers, and
trimers for gp120, gp140(-), and gp140(-)ATC are indicated with cartoons. (B) Expression analysis of H6.ATC. A mammalian expression vector encoding H6.ATC was transiently
transfected into HEK-293 cells. The culture supernatant was harvested 3 days after transfection and analyzed byWestern blot using an anti-histidine tag monoclonal antibody along
with H6.ATC puriﬁed from E. coli. (C) Assay of ATCase enzymatic activity. The EC50 values were calculated for the H6.ATC protein puriﬁed from E. coli, H6.ATC expressed in HEK-293
supernatants (from Fig. 2B), and gp140(-)ATC expressed in HEK-293 supernatants (from Fig. 1B). HEK-293 supernatant containing gp140(-) was used to determine background
activity.
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efﬁciency, its binding to b6 was clearly much lower than that of gp120
(Fig. 3). Taken together, our results indicate that all JRCSF gp140
variants show a trend toward stronger binding of the neutralizing
antibodies b12 and 2G12 and weaker reactivity with the non-
neutralizing antibody b6 antibody.
Antibody responses induced by various forms of JRCSF gp140
We immunized 6 rabbits with the plasmid encoding gp140 and 3
rabbits each with the plasmids encoding gp140(-), gp140(-)T4F,
gp140(-)ATC, and gp140(-)GCN followed by a single injection of
JRCSF gp120 protein. Sera were collected on Day 70 (2 weeks after the
third DNA injection) and Day 98 (2 weeks after the protein boost) and
used to analyze antibody binding to various antigens.
Plasmids expressing the various forms of JRCSF gp140 induced
similar levels of antibodies to gp120 at Day 70 (Fig. 4A, top left panel).
Although not statistically signiﬁcant, gp140 and gp140(-) gave
slightly better anti-gp120 responses than the three trimerized forms
of gp140(-). These small differences were not apparent after the
protein boost, which produced a 5- to 10-fold increase in the level of
gp120-binding antibodies.
Binding of the Day 70 sera was also tested against gp120 Core
protein, in which the V1/V2, V3, and about half of the C1 and C5
regions are deleted (Fig. 4A, bottom left panel, closed symbols). We
observed a larger spread in the binding activities, compared to gp120.
The gp140(-) immunogen induced the highest level of binding
antibodies and the gp140(-)GCN immunogen, the lowest. Thedifference in antibody levels induced by gp140(-) and gp140(-)GCN
was statistically signiﬁcant for all ﬁve dilution points in linear part of
the curves, (Pb0.05). The difference in antibody levels induced by
gp140(-) and gp140(-)ATC was also statistically signiﬁcant for three
out of the same ﬁve dilutions (Pb0.05).
The gp120 protein boost enhanced the Day 98 antibody responses
to gp120 Core by at least 10-fold for all ﬁve immunogens (Fig. 4A,
bottom left panel, open symbols). In contrast to the responses to
gp120, the differences among the anti-gp120 Core responses seen on
Day 70 were still observed on Day 98. The strongest anti-gp120 Core
response was given by the gp140(-)ATC immunogen, which was
boosted by more than 10-fold. These results suggest that modiﬁca-
tions of gp140 can affect the regions of gp120 that are immunogenic.
Both gp140(-) and gp140(-)ATC might be better immunogens for
V1/V2 and V3-independent responses than the other three gp140
variants tested.
We also analyzed the Day 70 sera for antibodies directed to the
gp41 ectodomain (Fig. 4A, top right panel, closed symbols). Based
on the levels of antibodies induced, the ranking of immunogens
is gp140Ngp140(-)Ngp140(-)GCNNgp140(-)T4FNgp140(-)ATC.
Although most of these differences are rather small, the difference
between gp140 (the strongest) and gp140(-)ATC (the weakest)
was statistically signiﬁcant for four out of the ﬁve dilution points in
the linear part of the curves (Pb0.03, respectively).
To illustrate the differences of the immune responses induced by
the several forms of gp140, we plotted the same set of data for each
immunogen (Fig. 4B). All ﬁve constructs induced clearly detectable
immune response to gp120, gp120 Core, and gp41 by Day 70. The
Fig. 3. Characterization mAb- and CD4-binding activities of gp120, gp140, gp140(-), and three trimeric gp140(-) proteins. Supernatants containing the Env proteins at a
concentration of 75 nM were used to coat ELISA plates. The plates were subsequently incubated with ten 1:2 dilutions of 2F5, 2G12, b6, b12, and CD4–Ig. An identical plate was
incubated in parallel with ten 1:2 dilutions of the polyclonal P31JR, beginning at 1:400, to determine the Env-coating efﬁciency. Representative data are shown from two
independent experiments.
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gp41 (Fig. 4B); the responses to gp120 Core were several fold weaker
than those to gp120 (Fig. 4B). The anti-gp41 responses induced by
gp140(-)ATC were very reproducible among the three animals
immunized (Fig. 4B, compare top right panel with others). The Day
70 sera from immunization with gp140(-)ATC exhibited a strong
antibody response to the ATC moiety (Fig. 4B, top right panel).
After the gp120 protein boost, gp140-primed rabbits continued to
have relatively strong responses to gp120 compared to gp120 Core,
whereas gp140(-) primed rabbits showed a similar antibody response
to gp120 and gp120 Core, suggesting that there is a qualitative
difference in the speciﬁcity of the antibodies induced between the two
types of immunogens (Fig. 4B, compare top left and top middle
panels). Among the three trimeric constructs, the gp140(-)T4F and
gp140(-)GCN immunogens induced higher antibody levels to gp120
compared to gp120 Core after the gp120 boost (Fig. 4B, compare top
middle and top right panels). However, the levels of antibody to
gp120 and gp120 Core induced by the gp140(-)ATC immunogen were
comparable, and in that respect, gp140(-)ATC was similar to gp140(-)
(Fig. 4B, compare top middle and top right panels).
Neutralizing antibody responses induced by various forms of JRCSF
gp140
We next measured the neutralization activities induced by the
various gp140 immunogens against a panel of ﬁve pseudoviruses
comprising 6535, BaL, JRCSF, NL4-3, and SF162. Protein boosting
clearly enhanced neutralizing titers, but the differences among the
groups suggested that DNA priming deﬁned the speciﬁcities (data not
shown). Consequently, only the Day 98 results are shown here
because of their higher titers (Fig. 5).
The cleavable and noncleavable forms of gp140 induced similar
neutralizing responses against three of the ﬁve pseudoviruses tested
(BaL, JRCSF, and SF162) but gp140(-) gave a signiﬁcantly stronger
neutralization response against 6535 (2.9-fold; P=0.015) and astronger trend against NL4-3 (2.5-fold; P=0.052). The neutralization
activities induced by gp140(-)T4F were indistinguishable from those
induced by gp140(-) on all ﬁve pseudoviruses tested (Fig. 5). The
gp140(-)GCN immunogen induced a signiﬁcantly lower neutraliza-
tion titer compared to gp140(-) against two out of ﬁve pseudoviruses
[6535 (3.2-fold; P=0.019) and NL4-3 (2.4-fold; P=0.008)] although
it gave a strong autologous neutralization response to JRCSF (Fig. 5).
Both gp140(-) and gp140(-)ATC elicited equally strong neutralizing
responses against 3 out of 5 pseudoviruses tested (6535, NL4-3, and
SF162) and gp140(-)ATC gave signiﬁcantly better neutralization
activity against BaL (1.8-fold; P=0.024) and a stronger trend against
JRCSF (4.2-fold; P=0.402). Overall, there was no signiﬁcant improve-
ment for any of the trimeric gp140(-) fusion constructs compared to
gp140(-).
We performed a second immunization study using the same
protocol as above but with eight rabbits per group to evaluate the
reproducibility of the results obtained with the constructs expressing
gp140, gp140(-), and gp140(-)ATC. The Day 98 sera were assayed
against three pseudoviruses, 6535, JRCSF, and NL4-3. Once again,
gp140(-) gave a signiﬁcantly stronger neutralization response
against 6535 (1.6-fold; P=0.018) and a stronger trend against NL4-
3 (1.5-fold; P=0.052) compared to gp140, although both immuno-
gens induced similar neutralization responses against JRCSF. The
gp140(-)ATC construct induced neutralizing activity against all three
viruses that was equivalent to or greater than that induced by either
the cleavable or uncleaved forms of gp140 (Fig. 6). Although not
statistically signiﬁcant, gp140(-)ATC once again induced higher
neutralizing titers against JRCSF (3.6-fold; P=0.173).
Discussion
An antibody-based preventative vaccine to HIV-1 should induce
broad and potent virus neutralizing responses (Burton et al., 2004;
Karlsson Hedestam et al., 2008; Monteﬁori et al., 2007; Walker and
Burton, 2008). It has been suggested that the inability of current Env
Fig. 4. Characterization of antibody responses induced by gp140, gp140(-), and three gp140(-) trimeric constructs. Plasmids encoding the indicated proteins were injected into
rabbits at 0, 28, and 56 days followed by a single gp120 protein boost on Day 84. Sera were collected at Day 70 and Day 98, and the antibody responses to JRCSF gp120 and JRCSF
gp120 Core were determined by ELISA. Day 70 sera were also used to analyze the antibody responses against the gp41 ectodomain. The Day 70 responses to ATC induced by
gp140(-)ATC were also analyzed. The data shown are the average and standard deviation of all animals within each group immunized with the same immunogen. (A)
Comparison of total antibody responses induced by different immunogens against each of the coating antigens. The coating antigens used for ELISA analyses are indicated in each
panel. (B) Comparison of total antibody responses induced by each immunogen against different coating antigens. The immunogens are indicated in each panel.
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to structural differences between the subunit vaccine component and
the functional trimeric Env complexes of the virus (KarlssonHedestam
et al., 2008; Moore et al., 2006; Poignard et al., 2003; Schulke et al.,
2002; Yang et al., 2002). It is generally thought that a truemimic of the
viral Env trimer should expose neutralizing epitopes including
conserved sites such as the one deﬁned by the b12mAb (Liu et al.,
2008; Moore et al., 2006; Poignard et al., 2003; Zanetti et al., 2006).
Largely driven by such a hypothesis, considerable effort has been
devoted to improving the trimerization of the soluble gp140ectodomain of Env (Dey et al., 2007, 2008; Iyer et al., 2007; Schulke
et al., 2002; Yang et al., 2000b, 2002). Four trimerization motifs (ATC,
CART, GCN, and T4F) have been reported to stabilize gp140(-) when
fused to the C-terminus of either JRFL, YU2, or SIVmac32H gp140
(Chen et al., 2004; Selvarajah et al., 2008; Yang et al., 2000a, 2002).We
have found that GCN, T4F, and ATC effectively enhance the trimeriza-
tion of JRCSF gp140(-). The trimerization of gp140(-)ATC was also
supported by the detection of ATCase enzymatic activity (Fig. 2).
Yang et al. previously demonstrated that fusion of YU2 gp140(-) to
GCN or T4F creates trimers that exhibit preferential binding of both
Fig. 5. Comparison of the neutralization responses induced by gp140, gp140(-), and the three trimeric gp140(-) fusion proteins. The Day 98 sera were tested in neutralization assays
against the ﬁve indicated pseudoviruses. IC50 neutralization titers were calculated and plotted for each serum–virus pair. The aMLV controls for all sera were negative (IC50≤10; not
shown). The geometric mean titer for each group of sera is shown as a horizontal bar. For statistical analysis, a two-tailed, two-sample equal variance Student's t-test was performed
using the log10 of the IC50 values. ⁎⁎Pb0.01; ⁎0.01bPb0.05.
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mimic the antigenicity of functional viral trimers (Yang et al., 2000b,
2002). Similarly, all three of the trimeric JRCSF gp140(-) fusion proteins
studied here exhibit a higher ratio of b12 to b6 binding compared to
gp120 (Fig. 3).However, these preferential bindingproﬁlesmightnot be
the result of improved trimerization of gp140(-) but rather be due to the
structural differences between gp120 and gp140(-). The gp140(-)
protein, which contains no trimerization domain, also shows an
antigenic proﬁle similar to that of the gp140(-) fused to trimerization
motifs (Fig. 3). Thus, although all three trimerization motifs clearly
improved trimer formation of gp140(-), trimerization did not result in a
substantial change in the antigenicity of gp140(-) as determined by the
binding of 2G12, b6, b12, and CD4–Ig (Fig. 3).
Previous studies using Env proteins from the YU2 and SF162
strains have shown that introduction of mutations at the furin
cleavage site between gp120 and the gp41 ectodomain was sufﬁcient
to stabilize oligomers, including trimers (Srivastava et al., 2003a; Yang
et al., 2000a). However, our BN-PAGE analysis shows that both JRCSF
gp140 and gp140(-) have a similar proportion of dimer, trimer, and
higher order oligomers (Fig. 2A, lanes 3 and 6), suggesting that simply
mutating the furin cleavage site is not be sufﬁcient to create trimers.
We compared the immunogenicity of gp140 and gp140(-) in two
independent rabbit studies and found that in both cases gp140(-)
elicited a statistically stronger neutralization response against 6535Fig. 6. Comparison of the neutralization responses induced by gp140, gp140(-), and the trime
immunize groups of eight rabbits three times followed by a single gp120 protein boost. Sera w
controls for all sera were negative (IC50≤10; not shown). The geometric mean titer for eaand a stronger trend against NL4-3 (Figs. 5 and 6). Therefore,
mutation of the furin-cleavage site appears to modestly affect the
induction of neutralizing antibodies against certain isolates. Analysis
of the Day 70 and Day 98 sera showed that while the gp140 and
gp140(-) constructs induced similar binding antibody responses
against gp120 and gp41, gp140(-) induced a stronger response to the
V1-, V2-, and V3-deleted gp120 Core (Fig. 4), which could partially
account for differences in neutralization activities.
Yang et al. reported that YU2 gp140(-)T4F and gp140(-)GCN are
more immunogenic than YU2 gp120 (Yang et al., 2000b, 2002). Such
improvements could be due to the improved trimerization of
gp140(-) afforded by T4F or GCN but might also be simply due to
the inclusion of the gp41 ectodomain (e.g., by providing additional
T-helper epitopes). We compared the immunogenicity of JRCSF
gp140(-) with or without trimerization motifs using a DNA prime
and protein boost protocol. The neutralization proﬁles of antibodies
induced by gp140(-) and gp140(-)T4F were essentially identical
while gp140(-)GCN showed reduced neutralization activity to
some viruses (Fig. 5). The results suggest that the enhancement
of trimer formation is not always accompanied by a beneﬁcial
effect on immunogenicity.
The size of a monomeric ATCase catalytic subunit is 34 kDa, and
use of this trimerization motif therefore adds 102 kDa to the size of
the gp140(-) trimer. This increased size had only a modest effect onric gp140(-)ATC fusion protein. Plasmids expressing the indicated proteins were used to
ere tested in neutralization assays against the three indicated pseudoviruses. The aMLV
ch group of sera is shown as a horizontal bar. ⁎0.01bPb0.05.
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moiety in gp140(-)ATC elicited a strong antibody response in rabbits
(Fig. 4), but this it did not mask the response to gp140(-). Compared
to gp140(-)T4F and gp140(-)GCN, gp140(-)ATC induced similar levels
of antibodies to gp120 and gp41 as measured by ELISA (Fig. 4).
Although gp140(-)ATC induced somewhat weaker responses to
gp120, gp120 Core, and gp41 than did gp140(-) on Day 70 (Fig. 4),
the responses to both gp120 and gp120 Core are indistinguishable;
this is similar to the pattern observed with the gp140(-) immunogen
(Fig. 4). Moreover, addition of ATC to gp140(-) resulted in a highly
reproducible anti-gp41 responses at Day 70 (Fig. 4).
Compared to the sera induced by gp140(-) at Day 98, sera from
immunization with gp140(-)ATC exhibited indistinguishable neutral-
ization responses against 6535, NL4-3, and SF162 as well as stronger
responses to BaL (1.8-fold; P=0.024) and JRCSF (4.2-fold; P=0.402)
(Fig. 5). Althoughnot statistically signiﬁcant, the improved response to
JRCSF induced by gp140(-)ATCwas observed in a separate studywith a
larger number of animals per group (3.6-fold; P=0.173) (Fig. 6). The
stronger neutralization response induced by gp140(-)ATC cannot,
however, be explained simply by the total antibody levels, whichwere
similar to those induced by gp140(-) on Day 98 (Fig. 4). Taken
together, our data suggest that there is a beneﬁcial effect of ATC on the
immunogenicity of gp140.
In summary, we conclude that trimer formation of wild-type
gp140 sequences has limited value for enhancing the ability of HIV-1
Env to induce broadly neutralizing antibodies. However, we have
compared immunogenicity using only uncleavable gp140(-), and we
cannot rule out the possibility that the lack of signiﬁcant improve-
ment found here might not apply to the cleavable form of gp140. A
logical next step is to improve immunogenicity by modifying the Env
sequences in the gp140ATC trimer. One potential approach is directed
molecular evolution, using in vitro DNA recombination to create
sequence variants followed by high-throughput screening of the
expressed chimeric proteins for desirable antigenic or structural
properties (Locher et al., 2004). The ATC motif will allow use of
enzymatic activity to identify gp140(-)ATC variants that form trimers.
Screening of tens or hundreds of immunogens in animals can
potentially identify vaccine candidates that exhibit an improved
ability to induce neutralizing antibodies to HIV-1.
Materials and methods
Expression vectors and JRCSF gp140 expression constructs
The mammalian expression vector pMAmp was used for both cell
culture transfection and DNA-based immunization of animals (Du et
al., 2008). This vector contains the CMV immediate-early promoter
and the corresponding viral intron, a Kozak initiator sequence, a
human tissue plasminogen activator signal sequence, an N-terminal
hexahistidine tag, and a poly(A) signal from bovine growth hormone.
Three in-frame restriction sites, AgeI, BsiWI and NgoMIV, were
engineered to facilitate cloning of gp140 genes and the coding
sequences of trimerization motifs.
The DNA sequence encoding gp140 from the JRCSF strain of HIV-1
was synthesized using codons chosen from highly expressed human
genes (Haas et al., 1996). The gp140 gene was cloned into pMAmp
using the AgeI and BsiWI restriction sites. The coding sequence for
noncleavable gp140(-) was created using an overlap PCR approach to
introduce the following mutations at both the primary and secondary
furin cleavage sites between gp120 and gp41: K488I, R489S, R490S,
E495S, and R497S (Srivastava et al., 2003a).
DNA sequences encoding the trimerization motifs were cloned
into pMAmp containing either gp140 or gp140(-) using the BsiWI and
NgoMIV sites so that these motifs were fused in frame at the C-
terminal end of the Env polypeptide coding sequence. For T4F and
GCN (Yang et al., 2000b, 2002), we designed two oligonucleotides foreach motif based on the T4 bacteriophage wac gene (GenBank
Accession No. NC_000866) and a Saccharomyces cerevisiae GCN4
mRNA (AF416613), respectively. The two oligonucleotides were
annealed to form a linker with engineered overhangs for directly
cloning into the BsiWI and NgoMIV sites. For the ATC motif, we
designed two primers to amplify the coding sequence from genomic
DNA of the E. coli K12 strain using a ChargeSwitch gDNAMini Bacteria
Kit (Invitrogen). The ampliﬁed fragment was then digested and
cloned into pMAmp containing either gp140 or gp140(-) using the
BsiWI and NgoMIV sites.
Cell culture and transient transfection
Human embryonic kidney HEK-293 cells (ATCC No. CRL-1573) and
African greenmonkey kidney ﬁbroblast-like COS-7 cells (ATCCNo. CRL-
1651) were maintained in Dulbecco's Modiﬁed Eagle Medium (Invitro-
gen) supplemented with 10% (v/v) fetal bovine serum, 100 U/ml of
penicillin and 100 μg/ml of streptomycin. Chinese Hamster Ovary-K1
cells (ATCC No. CCL-61)weremaintained in a 1:1mixture of Dulbecco's
Modiﬁed Eagle Medium/Nutrient Mixture F-12 (DMEM/F-12; Invitro-
gen) supplemented with 10% (v/v) fetal bovine serum, 100 U/ml of
penicillin and 100 μg/ml of streptomycin. All cell cultures were
maintained at 37 °C in a humidiﬁed incubator containing 5% CO2.
Cells were seeded 24 h before transfection at 50% conﬂuency in the
appropriate serum-containing medium. FuGENE 6.0 (Roche Applied
Sciences) was used for transient transfection of COS-7 cells and
Lipofectamine 2000 (Invitrogen) was used for HEK-293 cells accord-
ing to the manufacturer's instructions. For expression analysis, both
COS-7 and HEK-293 cells were directly transfected in serum-free
Opti-MEM I medium (Invitrogen) and incubated for 3 days at 37 °C.
Supernatants were harvested and clariﬁed by centrifugation at
3000 rpm (2500×g) for 10 min. Cellular extracts were prepared
using CelLytic-M lysis buffer (Sigma).
Human monoclonal antibodies
The isolation of the b6 and b12 human mAbs has been described
(Barbas et al., 1993; Burton et al., 1991; Roben et al., 1994). BothmAbs
recognize discontinuous epitopes that overlap the functionally
conserved CD4-binding site on gp120 (Pantophlet et al., 2003;
Roben et al., 1994). In this study, the IgG1 forms of b6 and b12 were
used. The humanmAbs 2F5 and 2G12, which recognize the conserved
tryptophan-rich MPER of gp41 (Muster et al., 1993; Ofek et al., 2004;
Pejchal et al., 2009) and a mannose-dependent epitope on gp120
(Scanlan et al., 2002; Trkola et al., 1996), respectively, were obtained
from Polymun Scientiﬁc (Vienna, Austria).
Expression and puriﬁcation of control proteins
The expression and puriﬁcation of both JRCSF gp120 and gp120
Core from CHO-K1 cells were following the methods described
previously (Du et al., 2008). The JRCSF gp120 Core gene was designed
based on the HXBc2 gp120 Core construct used for crystallization
studies (Kwong et al., 1998; Wyatt et al., 1998).
The coding sequence for ATC was subcloned into pQE-81L
(Qiagen) using the BamHI and HindIII sites in framewith the initiation
codon and the sequences encoding a N-terminal hexahistidine tag
provided by the vector. After transformation into E. coli XL-10 Gold
Ultracompetent cells (Stratagene), a single colony was picked and
inoculated into 50 ml of 2× YT (Sigma) supplemented with
carbenicillin (50 μg/ml) and glucose (0.5%). After incubation
overnight at 37 °C, 20 ml of the culture was inoculated into 100 ml
of 2× YT supplementedwith carbenicillin (50 μg/ml) and incubated at
37 °C for 1 h. IPTGwas then added to a ﬁnal concentration of 2mMand
incubation continued for 5 h at 37 °C. Cells were collected by
centrifugation at 3500 rpm (2500×g) at 4 °C for 20min and suspended
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passed three times through a French Pressure cell press (SLM Aminco
Instruments) under 1000–1500 psi. Insoluble material was removed
by centrifugation at 12,000 rpm (17,210×g) at 4 °C for 20 min using a
Sorvall SS-34 rotor. The clariﬁed cell lysate was loaded onto a 5 ml Hi-
Trap Ni-column (GE Healthcare) freshly charged with Ni++ running
on a BioLogic LP Chromatography System (BioRad). After washing
with 150 ml of 500 mM NaCl in 20 mM NaH2PO4 (pH 7.4) containing
25 mM imidazole, H6.ATC was eluted with 0.25 M imidazole in the
same buffer. The peak protein-containing fractions were buffer-
exchanged and concentrated to 10 mg/ml and stored at –80 °C. The
purity of the ﬁnal H6.ATC preparation was N95% as judged by SDS–
PAGE analysis.
The H6.ATC coding sequences were also cloned into pMAmp for
expression by transient expression in mammalian cells.
A CD4–Ig fusion protein was created as described (Byrn et al.,
1990) with some modiﬁcations. The coding sequence for the ﬁrst 26–
181 amino acids of human CD4 containing the V1J1 and V2J2 domain
of mature CD4 (Arthos et al., 1989) was ampliﬁed from resting CD14+
monocyte cDNA from a Human Blood Fractions MTC Panel (Clontech)
and ligated to the 5′ end of the coding sequence of human IgG1 Fc
constant region omitting the CH1 domain through an in-frame BstEII
site that introduced two amino acids, VT, before proline 212 in the
IgG1 hinge. The DNA fragment was cloned into pMAmp in frame with
the tissue plasminogen activator leader peptide coding sequence
using the NheI and XbaI sites. The resultant plasmid was cotransfected
with pPUR (Clontech) into CHO-K1. Stable CHO cell lines expressing
CD4–Ig were created and expanded to roller bottles for protein
production as described previously (Du et al., 2008). For puriﬁcation,
1 l of culture supernatantwas supplementedwith 0.5MNaCl, 1mMof
Pefabloc (Sigma), and 10 mM of benzamidine (Sigma). The superna-
tant was ﬁltered on a 0.22-μm membrane and loaded onto a 5 ml
HiTrap Protein A FF column (GE Healthcare) equilibrated with PBS
(pH 7.4) using a BioLogic LP system. The column was washed with
80 ml of 1.5 M glycine–NaOH buffer (pH 9.0) containing 3 M NaCl and
eluted with 0.2 M glycine–HCl buffer (pH 2.5). The eluate was
immediately neutralized by 1/10 volume of 1 M Tris–HCl buffer (pH
9.0) that was preadded to the collection tubes. The peak protein-
containing fractions were buffer-exchanged and concentrated to 0.5–
1.0 mg/ml and stored at –80 °C. The purity of the ﬁnal CD4–Ig
preparation was N90% as judged by SDS–PAGE analysis.
Western blot analysis and quantitation of molar expression
Transfection supernatants were separated on 4%–12% SDS–PAGE
gels and the gp140 polypeptide was visualized by Western blot using
either a mouse polyclonal anti-gp120 serum or an anti-histidine tag
monoclonal antibody (GE Healthcare) as described previously (Du et
al., 2008). For quantitation of expression, 3–4 different dilutions of
each supernatant were compared to 6 serial 1:2 dilutions of puriﬁed
JRCSF gp120 with a starting concentration of 200 nM on the same
Western blot. Each Western blot image was scanned and saved as a
noncompressed TIFF ﬁle. After the intensities of Env-speciﬁc bands
were quantitated using Phoretix Array 3.0 (Nonlinear Dynamics), a
standard curve was generated from the gp120 controls using
nonlinear regression curve ﬁtting (GraphPad Prism 5.0) and the
molar expression level in nM of gp140 variant in each supernatant
was calculated.
Determination of trimer formation by BN-PAGE analysis
JRCSF gp140 variants were transiently expressed in COS-7 cells
and puriﬁed on lectin columns. For each puriﬁcation run, a disposable
column was prepared using 200 μl of G. nivalis Agglutinin–agarose 4%
resin suspension (Sigma) in a 5 ml polypropylene column with a
porous polyethylene disc (Pierce). After resin storage buffer wasallowed to drain by gravity, the column was washed three times with
PBS (pH 7.4) supplemented with 0.1 mM CaCl2. Fifteen milliliters of
culture supernatant containing gp140 or gp140 fusion proteins were
centrifuged at 4000 rpm for 15 min and loaded on the column by
gravity. The ﬂow-through was collected and passed over the column
one more time. The column was then washed three times with PBS
(pH 7.4) supplementedwith 0.1mMCaCl2 and elutedwith 1ml of 1M
α-methyl mannoside (Sigma) in PBS. The eluate was injected into a
Dialysis Cassette (Pierce) and dialyzed in PBS at 4 °C overnight. The
recovered protein was further concentrated 25-fold using Microcon
YM-50 centrifugal ﬁlter devices (Millipore) and stored at –70 °C.
BN-PAGE analysis was performed as described in detail previously
(Moore et al., 2006) except that for this study the Western blot steps
following BN-PAGE separation were omitted since puriﬁed proteins
were used. Brieﬂy, protein samples were mixed with an equal volume
of 2× sample buffer containing 100 mM morpholinepropanesulfonic
acid, 100 mM Tris–HCl, pH 7.7, 40% glycerol, and 0.1% Coomassie blue
and loaded onto a 4%–12% Bis–Tris NuPAGE gel (Invitrogen). Ferritin
(GE Healthcare) was used as a size standard. Electrophoresis was
carried out at 4 °C for 3 h at 100 V with 50 mM morpholinepropa-
nesulfonic acid, 50mM Tris–HCl, pH 7.7, containing 0.002% Coomassie
blue as cathode buffer and the same buffer without Coomassie blue as
the anode buffer. Gels were destained and dried.
ATCase assays
A 96-well ATCase assay was adapted from an original method
(Prescott and Jones, 1969) modiﬁed for use with microtiter plates
(Else and Herve, 1990). All chemicals used in the assay were
purchased from Sigma unless speciﬁed otherwise. Since three ATCase
catalytic subunits are required to form one enzymatic site (Helm-
staedt et al., 2001), the molar concentration used here is that of the
trimer, although not all monomers will form trimers. The starting
concentrations of puriﬁed H6.ATC from E. coli, H6.ATC expressed in
HEK-293 supernatant, and gp140(-) or gp140(-)ATC expressed in
HEK-293 supernatants were 93, 371, and 741 nM, respectively. A 12-
point 1:2 dilution series of each sample (ﬁnal volume of 50 μl) was
prepared in OptiMEM I medium lacking phenol red (Invitrogen) in a
96-well U-bottom MaxiSorp plate (Nalge Nunc International). The
assay plate was sealed and preincubated at 37 °C for 30 min. To each
well was added 100 μl of freshly prepared substrate buffer containing
15 mM carbamyl phosphate and 30 mM L-aspartate in dilution buffer
(40 mM Tris-acetate, 1 mM EDTA, 376 pM BSA, 1 mM mercaptoetha-
nol, pH 8.3). After incubation at 37 °C for 30 min, 100 μl of freshly
prepared color mix (2 parts of 0.5 % (w/v) antipyrine in 3 M H2SO4
and 1 part of 0.8 % (w/v) diacetyl monoxime in 5% (v/v) acetic acid)
was added to each well. The plate was immediately sealed and color
reactions were developed at 60 °C in an ISOTMP forced air incubator
(Fisher) for 3 h. Colorimetric signals were acquired at 450 nm. The
EC50 for each sample was calculated in GraphPad Prism 5.0 using the
log(agonist) versus response nonlinear regression model with
variable slope based on triplicate assay results.
ELISA analysis of mAb- and CD4-binding activities
Plasmid constructs expressing JRCSF gp120, gp140, and the four
gp140(-) variantswere transiently transfected into HEK-293 cells. The
nM expression levels of Env in the harvested supernatants were
quantitated and normalize to 75 nM using Opti-MEM I. Normalized
supernatants were used to coat 96-well U-bottom MaxiSorp plates,
50 μl per well, at 4 °C overnight. The coated plates were covered with
200 μl of blocking buffer (5% nonfat milk in 1× PBS plus 0.5% Tween
20) for 3 h and then incubated at room temperature for 30 min with
1:2 serially diluted antibodies (2F5, 2G12, b6, or b12) or CD4–Ig in the
blocking buffer. Binding was visualized by incubation at room
temperature for 30 min with an anti-human IgG conjugated with
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freshly prepared TMB substrate (Pierce) at room temperature for 10
min. Colorimetric signals were acquired at 450 nm. Most of liquid
handling procedures were carried out by a Tecan Genesis 100 robotic
station.
We ﬁrst tested a wide range of concentrations for each ligand to
determine a proper dilution range: 0.01 to 20.00 μg/ml for 2G12, b6,
and b12 and 0.04 to 80.00 μg/ml for 2F5 and CD4–Ig. We chose
starting concentration of 0.25, 0.25, 0.50, and 10.00 μg/ml for b6, b12,
2G12, and CD4–Ig, respectively, to show a full range of binding
(baseline to plateau) for gp140 variants as well as the gp120 control.
For 2F5, the binding activities did not reach plateau even at a
concentration of 80 μg/ml, which we chose as the starting
concentration.
An additional plate was also prepared for each ELISA run to
establish the coating efﬁciencies of the Env proteins in the super-
natants. We used 1:2 dilutions of a polyclonal immune serum to JRCSF
gp120, called P31JR, that was made by pooling sera from ﬁve rabbits
immunized with JRCSF gp120 using the standard DNA electroporation
and protein boost protocol. The gp120-binding signals were visual-
ized using the same procedures as described above except that an
anti-rabbit IgG conjugated with horseradish peroxidase (1:5000; GE
Healthcare) was used as the secondary antibody.
All data analysis was performed using Microsoft Excel and
GraphPad Prism 5.0.
Rabbit immunizations
Selected plasmid constructs expressing gp140 variants were used
for milligram-scale endotoxin-free DNA preparation and subsequent
immunization at Aldevron LLC (Fargo, ND) using protocols approved
by the local Animal Care and Use Committee. Certiﬁed parasite-free
female New Zealand White rabbits were obtained at 8 weeks of age
with an average weight of 1.8–2.3 kg. After a 1-week acclimation
period, each rabbit was immunized with a total 400 μg of DNA using
electroporation on Days 0, 28, and 56 (200 μg DNA injected in each of
the triceps brachii). On Day 84, each rabbit received a total of 100 μg of
recombinant JRCSF gp120 in 200 μl of PBS (pH 6.8) mixed with 200 μl
of AS02A 2× (Voss et al., 2003) injected intramuscularly (50 μg in each
of the hind muscles). Bleeds were obtained at Day 0, at 2 weeks after
the third DNA injection (Day 70), and at 2 weeks after protein
boosting (Day 98).
ELISA analysis of antibody responses in rabbit sera
Puriﬁed JRCSF gp120, JRCSF gp120 Core, HXB2 gp41 ectodomain
(Fitzgerald Industries International), andH6.ATCwere used to coat 96-
well U-bottom MaxiSorp plates, 100 ng in 50 μl per well, at 4 °C
overnight. The coated plates were then covered with the blocking
buffer and incubated for 3 h at room temperature. The plates were
washed and incubated at room temperature for 30 min with twelve
1:4 serial dilutions of the Day 70 and Day 98 sera in blocking buffer at
an initial concentration of 1:4. The antibody binding was visualized by
incubation at room temperature for 30 min with the anti-rabbit IgG
conjugated with horseradish peroxidase (1:5000) followed by
incubation with the freshly prepared TMB substrate at room
temperature for 10min. Colorimetric signals were acquired at 450 nm.
Virus neutralization assays
The neutralizing activities of rabbit sera were analyzed at
Monogram Biosciences, Inc. using a pseudovirus-based neutralization
assay as previously described (Frost et al., 2005; Richman et al., 2003).
Brieﬂy, serial dilutions of rabbit sera are incubated with individual
pseudoviruses for 18 h at 37 °C. The mixtures are used to infect U87
cells expressing CD4 plus the CCR5 and CXCR4 coreceptors. Virusinfectivity is determined 72 h postinoculation by measuring the
amount of luciferase activity expressed in infected cells. Neutraliza-
tion activity is calculated by plotting the percent inhibition of
luciferase activity versus serum or antibody concentration (1/
dilution). The percent inhibition is derived as follows: [1− (luciferase
activity in the presence of serum or antibody/luciferase activity in the
absence of serum or antibody)] × 100. Inhibition curves deﬁned by the
four-parametric sigmoidal function: f(x)=a − [b/(1+(x/c)d)] are
ﬁtted to the data by nonlinear least squares and bootstrapping and
used to calculate the serum or antibody concentration required to
inhibit virus infectivity by 50%. Neutralization titers are expressed as
the reciprocal of the serum dilution conferring 50% inhibition (IC50).
A pseudovirus containing a non-HIV retroviral envelope from the
amphotropicmurine leukemia virus (aMLV) is included in the assay of
each serum as a negative control. The IC50 value is considered positive
if the percentage of neutralization is 3-fold greater than the aMLV
control. Negative sera and sera that failed to reach 50% neutralization
are assigned a value of 10, which is the lowest dilution tested for each
serum. Two-tailed homoscedastic t-test analyses were performed in
Excel.
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